China SXT Pharmaceuticals, Inc.
SXTCHealthcare|Drug Manufacturers - Specialty & Generic|CN
$2.83
-0.10 (-3.41%)
DCF Value
$3537.77
Tangible Book / Share
$5070.18
Cash / Share
$4809.87
Financials
Financial Snapshot
Market Cap
$15.1K
Enterprise Value
-$27.0M
Revenue (TTM)
$1.1M
Net Income (TTM)
-$6.2M
Cash & Investments
$28.2M
Net Cash
$27.1M
Free Cash Flow (TTM)
-$6.0M
Operating CF (TTM)
-$6.0M
Debt/Equity
0.04
Cash Runway & Burn Rate
Cash on Hand
$28.2M
Quarterly Burn
$1.5M
Monthly Burn
$502.2K
Est. Runway
~18.7 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $65.6K | $560.3K | $9.1M | $7.3M | $13.3M | $15.5M | $17.4M | $12.1M | $18.1M | $28.2M | $28.2M | |
| Operating Cash Flow | $293.0K | $1.9M | $239.2K | $934.2K | -$1.3M | -$2.4M | -$80.8K | -$1.9M | -$2.3M | -$4.0M | -$6.0M | |
| Free Cash Flow | $106.7K | $869.4K | -$370.9K | $527.6K | -$1.4M | -$2.4M | -$151.4K | -$1.9M | -$2.3M | -$4.0M | -$6.0M | |
| Capital Expenditure | -$186.3K | -$1.1M | -$610.1K | -$406.7K | -$93.0K | -$62.5K | -$70.7K | -$7.1K | -$2.0K | -$4.00 | -$4.00 | |
| Financing Cash Flow | -$50.6K | -$314.2K | $9.0M | $3.0M | $12.4M | $1.6M | $2.9M | -$2.6M | $8.4M | $14.4M | $21.7M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $7.0M | $7.0M | $5.2M | $4.8M | $2.6M | $2.0M | $1.9M | $1.7M | $1.1M | $1.1M | |
| Cost of Revenue | $2.6M | $3.6M | $2.4M | $2.5M | $1.9M | $1.4M | $1.5M | $1.4M | $1.4M | $889.4K | $889.4K | |
| Gross Profit | $2.3M | $3.4M | $4.6M | $2.7M | $2.8M | $1.3M | $426.3K | $554.0K | $367.4K | $183.3K | $183.3K | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $184.2K | $191.4K | $178.8K | $0.00 | |
| SG&A | $709.8K | $1.8M | $2.8M | $4.0M | $5.0M | $6.4M | $6.0M | $3.1M | $3.0M | $7.1M | $11.5M | |
| Operating Income | $1.6M | $1.6M | $1.8M | -$1.3M | -$2.2M | -$5.2M | -$5.6M | -$2.5M | -$2.7M | -$7.1M | -$10.7M | |
| Interest Expense | $40.4K | $779.00 | $5.2K | $3.3M | $1.6M | $36.7K | $476.8K | $544.3K | $648.2K | $63.0K | $63.0K | |
| Pretax Income | $1.6M | $1.6M | $1.8M | -$10.4M | -$2.9M | -$5.4M | -$5.9M | -$3.1M | -$3.3M | -$6.1M | -$6.1M | |
| Net Income | $1.2M | $1.2M | $1.5M | -$10.3M | -$2.7M | -$5.7M | -$5.9M | -$3.1M | -$3.3M | -$6.2M | -$6.2M | |
| EPS (Diluted) | 9980.00 | 10001.00 | 14967.00 | -83208.00 | -9548.00 | -13792.00 | -2223.00 | -357.00 | -818.00 | -913.00 | -795.00 | |
| EBITDA | $1.7M | $1.8M | $2.0M | -$1.0M | -$1.9M | -$5.1M | -$5.2M | -$2.4M | -$2.6M | -$7.0M | -$7.0M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.6K | $560.3K | $9.1M | $7.3M | $13.3M | $15.5M | $17.4M | $12.1M | $18.1M | $28.2M | $28.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $4.9M | $6.1M | $15.6M | $19.6M | $23.2M | $22.5M | $19.5M | $14.2M | $21.3M | $34.5M | $34.5M | |
| Total Assets | $5.4M | $7.7M | $17.5M | $21.7M | $34.5M | $33.5M | $29.6M | $23.1M | $21.7M | $34.8M | $34.8M | |
| Total Current Liabilities | $3.6M | $4.4M | $6.3M | $12.3M | $18.6M | $17.1M | $14.5M | $8.9M | $6.0M | $4.3M | $4.3M | |
| Long-Term Debt | $0.00 | $0.00 | $41.7K | $36.5K | $6.3K | $0.00 | $117.9K | $117.1K | $96.3K | $644.4K | $644.4K | |
| Total Liabilities | $3.6M | $4.4M | $6.4M | $12.3M | $18.6M | $17.1M | $14.9M | $9.2M | $6.2M | $5.0M | $5.0M | |
| Stockholders' Equity | $1.9M | $3.3M | $11.1M | $9.4M | $16.0M | $16.4M | $14.7M | $13.9M | $15.4M | $29.7M | $29.7M | |
| Retained Earnings | $357.1K | $1.5M | $3.1M | -$7.2M | -$10.0M | -$15.7M | -$21.6M | -$24.7M | -$28.0M | -$34.2M | -$34.2M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $293.0K | $1.9M | $239.2K | $934.2K | -$1.3M | -$2.4M | -$80.8K | -$1.9M | -$2.3M | -$4.0M | -$6.0M | |
| Capital Expenditure | -$186.3K | -$1.1M | -$610.1K | -$406.7K | -$93.0K | -$62.5K | -$70.7K | -$7.1K | -$2.0K | -$4.00 | -$4.00 | |
| Free Cash Flow | $106.7K | $869.4K | -$370.9K | $527.6K | -$1.4M | -$2.4M | -$151.4K | -$1.9M | -$2.3M | -$4.0M | -$6.0M | |
| Investing Cash Flow | -$186.3K | -$1.1M | -$610.1K | -$5.5M | -$5.8M | -$46.9K | -$12.3K | $26.4K | $63.5K | -$1.3M | -$1.9M | |
| Financing Cash Flow | -$50.6K | -$314.2K | $9.0M | $3.0M | $12.4M | $1.6M | $2.9M | -$2.6M | $8.4M | $14.4M | $21.7M | |
| Issuance of Stock | $0.00 | $0.00 | $6.5M | $0.00 | $0.00 | $0.00 | $2.2M | $0.00 | $2.8M | $14.3M | $14.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$50.6K | -$314.2K | $69.5K | $8.8M | -$124.9K | $0.00 | $4.0M | $1.3M | -$65.1K | $144.2K | $144.2K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $554.6K | $352.1K | $0.00 | $0.00 | $2.7M | |
| Net Change in Cash | $54.1K | $494.7K | $8.6M | -$2.0M | $6.1M | -$399.1K | $1.8M | -$5.3M | $6.1M | $10.0M | $13.5M |
Dilution Tracker
Shares outstanding grew 2259.7% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+2259.7%
Stock Issuance (TTM)
$14.3M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | |
| Change vs Prior % | — | 0.0% | -13.4% | 20.4% | 132.3% | 44.4% | 541.8% | 224.9% | -53.4% | 68.3% | -13.8% | |
| Stock Issuance | $0.00 | $0.00 | $6.5M | $0.00 | $0.00 | $0.00 | $2.2M | $0.00 | $2.8M | $14.3M | $14.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $554.6K | $352.1K | $0.00 | $0.00 | $2.7M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 47.4% | 48.5% | 65.8% | 52.4% | 59.4% | 48.1% | 21.6% | 28.7% | 21.1% | 17.1% | 17.1% | |
| Operating Margin % | 32.8% | 23.3% | 25.2% | -26.0% | -46.0% | -199.4% | -284.4% | -130.4% | -154.0% | -664.1% | -996.1% | |
| Net Margin % | 24.3% | 16.9% | 22.0% | -199.3% | -57.5% | -220.4% | -301.0% | -160.7% | -189.8% | -578.5% | -578.5% | |
| EBITDA Margin % | 34.9% | 25.1% | 28.2% | -19.6% | -38.8% | -194.1% | -264.1% | -121.9% | -147.8% | -650.7% | -650.7% | |
| FCF Margin % | 2.2% | 12.4% | -5.3% | 10.2% | -29.5% | -93.6% | -7.7% | -100.3% | -134.8% | -374.5% | -561.8% | |
| ROE % | 64.0% | 36.1% | 13.9% | -109.4% | -17.2% | -34.9% | -40.4% | -22.2% | -21.4% | -20.9% | -24.8% | |
| ROA % | 21.8% | 15.5% | 8.8% | -47.4% | -8.0% | -17.1% | -20.1% | -13.4% | -15.2% | -17.9% | -17.9% | |
| ROIC % | 55.8% | 32.4% | 10.9% | -8.2% | -12.8% | -19.1% | -30.4% | -15.2% | -16.3% | -23.1% | -26.8% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 9.6% | 11.0% | 16.7% | 0.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.3% | 43.8% | -0.1% | -26.4% | -7.5% | -45.5% | -24.2% | -2.2% | -9.7% | -38.4% | |
| Gross Profit | 191.2% | 47.1% | 35.6% | -41.4% | 5.0% | -55.9% | -65.9% | 30.0% | -33.7% | -50.1% | |
| Operating Income | 666.1% | 1.9% | 8.4% | -175.8% | -63.8% | -136.2% | -8.1% | 55.1% | -6.6% | -165.7% | |
| Net Income | 737.3% | 0.2% | 29.6% | -768.4% | 73.3% | -108.7% | -3.5% | 47.8% | -6.6% | -87.8% | |
| EPS (Diluted) | -10.9% | 0.2% | 49.7% | -655.9% | 88.5% | -44.4% | 83.9% | 83.9% | -129.1% | -11.6% | |
| Operating Cash Flow | 60.6% | 555.3% | -87.5% | 290.6% | -240.9% | -80.4% | 96.6% | -2287.5% | -21.6% | -71.3% | |
| Free Cash Flow | 24.9% | 714.6% | -142.7% | 242.2% | -367.2% | -72.9% | 93.8% | -1177.8% | -21.3% | -71.1% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.9% | -6.6% | |
| SG&A Expense | 21.4% | 149.3% | 60.6% | 42.3% | 24.5% | 27.9% | -6.3% | -49.1% | -0.7% | 133.8% | |
| Total Assets | -13.7% | 41.0% | 128.1% | 24.2% | 59.2% | -2.9% | -11.9% | -21.7% | -6.3% | 60.4% | |
| Book Value / Share | -72.8% | 77.4% | 290.6% | -29.7% | -26.9% | -28.8% | -86.1% | -70.8% | 138.0% | 14.4% | |
| Debt | -36.9% | 27.5% | 623.2% | 141.4% | -99.4% | 24643.3% | -65.0% | -29.5% | -62.8% | 13.9% | |
| Diluted Shares | 815.4% | 0.0% | -13.4% | 20.4% | 132.3% | 44.4% | 541.8% | 224.9% | -53.4% | 68.3% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High8428085.79 / 11019624.44 / 11042812.02
P/S0.01
10Y Low / Med / High85.15 / 258312.28 / 2686592.77
P/B0.00
10Y Low / Med / High3.07 / 141838.86 / 7078883.08
EV/EBITDA3.87
10Y Low / Med / High6570122.48 / 7444302.11 / 7708115.42
EV/Revenue-25.21
10Y Low / Med / High59.93 / 258312.17 / 2686592.82
P/FCFAt Loss
10Y Low / Med / High2527492.43 / 15084105.58 / 122872415.69
Intrinsic Value Models (per share)
DCF Value
$3537.77
Tangible Book / Share
$5070.18
Net Current Assets / Share
$5517.34
Graham Net-Net
$4614.45
Cash / Share
$4809.87
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 11042812.02 | 11019624.44 | 8428085.79 | -129240.56 | -925004.32 | -97447.14 | -30617.87 | -44638.43 | -3659.95 | -14.72 | -0.00 | |
| P/S Ratio | 2686592.77 | 1868387.29 | 1852923.18 | 258312.28 | 532404.02 | 214850.07 | 92169.97 | 71676.63 | 6945.87 | 85.15 | 0.01 | |
| P/B Ratio | 7078883.08 | 3991345.85 | 1169700.40 | 141838.86 | 159359.33 | 34040.19 | 12369.88 | 9922.74 | 783.18 | 3.07 | 0.00 | |
| EV/EBITDA | 7708115.42 | 7444302.11 | 6570122.48 | -1321215.76 | -1373677.15 | -110684.67 | -34892.79 | -58791.22 | -4692.72 | -9.21 | 3.87 | |
| EV/Revenue | 2686592.82 | 1868387.27 | 1852922.27 | 258312.17 | 532401.24 | 214848.23 | 92163.07 | 71671.75 | 6936.04 | 59.93 | -25.21 |
Analyst Estimates & Quality
Altman Z-Score
-0.98
Distress
Piotroski F-Score
4
Moderate
Revenue Segments
By Product
| Segment | 2026 |
|---|---|
| Others | $7.1K |